AstraZeneca to provide EU with extra nine million doses of COVID-19 vaccine following dispute
After manufacturing delays, AstraZeneca will now provide the EU with the 40 million COVID-19 vaccine doses it originally agreed to supply.
List view / Grid view
After manufacturing delays, AstraZeneca will now provide the EU with the 40 million COVID-19 vaccine doses it originally agreed to supply.
In vitro neutralisation assays show REGEN-COV and AZD7442 are effective against the new SARS-CoV-2 variants, while other antibody therapies, including Eli Lilly’s bamlanivimab, were not.
AbbVie's RINVOQ (upadacitinib) has been approved in the EU to treat adult patients with active psoriatic arthritis (PsA).
Pharmacist Ezeokafor Ifeoma Charity explores to what extent COVID-19 has prompted the growth of the pharmaceutical industry.
Amgen has set out the company's seven-year environmental sustainability plan to achieve carbon neutrality by 2027.
Research shows that the antibodies induced by the Pfizer-BioNTech COVID-19 vaccine can neutralise SARS-CoV-2 viruses with the N501Y mutation.
Analysts say M&A deals continue to be a core driver of pharma/biopharma industry growth and that 2021 will likely be another year of high deal value.
11 December 2020 | By Metabolon
Watch our on-demand webinar as experts discuss the use and benefits of incorporating untargeted and targeted metabolomics into the drug development process.
The European Commission has fined Teva and Cephalon €60.5 million for a pay-for-delay deal over Cephalon's modafinil and Teva's generic.
In this Q&A, Nick Pike, Chief Revenue Officer at Vizibl, outlines with EPR’s Hannah Balfour the benefits of Software as a Service (SaaS) for pharmaceutical companies and describes how its adoption can enable companies to achieve many goals faster; from collaborating on bringing new products to market to reaching their…
Mary Alice Dwyer and Sameer Lal explain how pharmaceutical companies can embrace a more customer-centric approach through digital transformation.
Following approval by Emisphere shareholders, Novo Nordisk will acquire the company for a total of $1.8 billion.
11 November 2020 | By Thermo Fisher Scientific
In this on-demand webinar we explore the evolving role of handheld and portable instruments to drive quality improvements and manufacturing success in 2021.
The acquisition will strengthen Merck’s oncology pipeline with VLS-101, an investigational antibody-drug conjugate in trials for haematological malignancies and solid tumours.
PhRMA has released a statement following the announcement that Joe Biden will be the next President of the US.